Curated News
By: NewsRamp Editorial Staff
April 15, 2026
NeuroOne and University of Minnesota Pioneer sEEG-Based Epilepsy Drug Delivery
TLDR
- NeuroOne's collaboration with the University of Minnesota could give the company a first-mover advantage in developing precise, brain-targeted epilepsy therapies that reduce systemic side effects.
- The study uses NeuroOne's sEEG platform to deliver novel therapeutics directly into specific brain regions, aiming to improve efficacy while lowering toxicity through localized intracerebral infusion.
- This research could lead to more precise, individualized epilepsy treatments that minimize side effects, offering patients better outcomes and improved quality of life through targeted brain therapy.
- Scientists are testing ultra-thin electrodes to deliver drugs directly into seizure networks, potentially creating a new era of precision brain therapy for epilepsy patients.
Impact - Why it Matters
This collaboration matters because it addresses a critical gap in epilepsy treatment by focusing on localized drug delivery, which could significantly reduce systemic side effects and improve precision for patients. Epilepsy affects millions worldwide, and current treatments often involve medications with broad impacts on the body, leading to adverse reactions and limited efficacy. By targeting specific brain regions involved in seizures, this approach has the potential to enhance therapeutic outcomes, minimize toxicity, and offer more personalized care. If successful, it could pave the way for new standards in neurological therapies, benefiting patients with drug-resistant epilepsy and reducing healthcare burdens through fewer hospitalizations and improved quality of life. This innovation aligns with broader trends in precision medicine, highlighting how advanced medical technologies can transform chronic disease management.
Summary
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company specializing in neurological disorder treatments, has announced a groundbreaking collaboration with the University of Minnesota Medical School's Department of Neurology's Division of Epilepsy. This partnership aims to advance a study evaluating next-generation epilepsy therapies using NeuroOne's innovative sEEG-based platform for localized drug delivery. The program is led by Dr. Sandipan Pati, Professor and Epilepsy Division Director, who is at the forefront of epilepsy care and research, bringing academic expertise and clinical insight to this pioneering initiative.
The core focus of this collaboration is on testing novel therapeutics delivered directly into specific brain regions involved in sustaining seizures, with the goal of improving clinical efficacy while reducing systemic toxicity and off-target effects. The study is expected to begin with large animal models and, if primary objectives are met, progress to human studies shortly thereafter. Dr. Pati emphasized that localized intracerebral delivery represents an important emerging direction for enhancing precision in epilepsy treatment, potentially minimizing systemic side effects and offering more individualized therapies for patients. NeuroOne's President and CEO, Dave Rosa, highlighted the University of Minnesota's leadership in next-generation epilepsy research, expressing optimism that this collaboration could support the development of a first-in-human study utilizing their technology, which might redefine seizure care and establish a new era of precision brain-directed therapy.
NeuroOne's technology platform includes FDA-cleared products such as Evo® Cortical Electrodes, Evo® sEEG Electrodes, and the OneRF® Ablation System, which are designed to reduce hospitalizations, lower costs, and improve patient outcomes through combination diagnostic and therapeutic functions. The company is actively engaged in research and development for drug delivery and spinal cord stimulation programs, with more information available at nmtc1.com. This news release was distributed via NEWMEDIAWIRE, and the original release can be viewed on www.newmediawire.com, underscoring the significance of this collaboration in the medical technology and epilepsy treatment fields. The forward-looking statements in the release caution about potential risks and uncertainties, but the overall message points to a promising step toward transformative neurological care.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroOne and University of Minnesota Pioneer sEEG-Based Epilepsy Drug Delivery
